Pfizer's Ibrance, under threat from Novartis and Lilly, leans on real-world data in breast cancer
Pfizer's Ibrance, used alongside Novartis’ hormone therapy Femara, cut the risk of death by 34% in women with HR-positive, HER2-negative metastatic breast cancer, real-world data show.